{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:40:36Z","timestamp":1780472436589,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.clinthera.2011.09.001","type":"journal-article","created":{"date-parts":[[2011,10,2]],"date-time":"2011-10-02T22:54:27Z","timestamp":1317596067000},"page":"1516-1523","source":"Crossref","is-referenced-by-count":17,"title":["Bioavailability and Short-Term Tolerability of Alendronate in Glucocorticoid-Treated Children"],"prefix":"10.1016","volume":"33","author":[{"given":"Meranda","family":"Nakhla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Denker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D.","family":"Walson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo G.","family":"Porras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Z.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.09.001_bib1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1359\/jbmr.2003.18.5.913","article-title":"Children and the risk of fractures caused by oral corticosteroids","volume":"18","author":"van Staa","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2011.09.001_bib2","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1210\/jc.2004-2054","article-title":"Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I","volume":"90","author":"Ward","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2011.09.001_bib3","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.09.001_bib4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.09.001_bib5","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2004-1659","article-title":"Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial","volume":"90","author":"Golden","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2011.09.001_bib6","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J","article-title":"Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study","volume":"43","author":"Bianchi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2011.09.001_bib7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/rheumatology\/keh538","article-title":"Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment","volume":"44","author":"Rudge","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2011.09.001_bib8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0031-3955(16)36251-4","article-title":"The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents","volume":"34","author":"Schwartz","year":"1987","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.clinthera.2011.09.001_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0378-4347(92)80551-Z","article-title":"Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and high-performance liquid chromatography with fluorescence and electrochemical detection","volume":"583","author":"Kline","year":"1992","journal-title":"J Chromatogr"},{"key":"10.1016\/j.clinthera.2011.09.001_bib10","series-title":"Therapeutic Products Directorate Guidelines: ICH Harmonised Tripartite Guideline: General Considerations for Clinical Trials","year":"1997"},{"key":"10.1016\/j.clinthera.2011.09.001_bib11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","article-title":"Studies of the oral bioavailability of alendronate","volume":"58","author":"Gertz","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.09.001_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00003088-199936050-00002","article-title":"Pharmacokinetics of alendronate","volume":"36","author":"Porras","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2011.09.001_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJM199903043400914","article-title":"Gamma\/delta T-cell stimulation by pamidronate","volume":"340","author":"Kunzmann","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.09.001_bib14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2011.09.001_bib15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s10067-008-0864-6","article-title":"Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases","volume":"27","author":"Inoue","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2011.09.001_bib16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/107999003322558782","article-title":"Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6","volume":"23","author":"Dicuonzo","year":"2003","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.clinthera.2011.09.001_bib17","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2014new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.09.001_bib18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1515\/jpem-2006-190410","article-title":"Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis","volume":"19","author":"Unal","year":"2006","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2011.09.001_bib19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MPH.0b013e318142b7a1","article-title":"Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience","volume":"29","author":"Lethaby","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.clinthera.2011.09.001_bib20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.apmr.2004.04.021","article-title":"Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy","volume":"86","author":"Hawker","year":"2005","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.clinthera.2011.09.001_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1399-3046.2004.00191.x","article-title":"Treatment of osteopenia and osteoporosis in renal transplant children and adolescents","volume":"8","author":"El-Husseini","year":"2004","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.clinthera.2011.09.001_bib22","first-page":"166","article-title":"Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling","volume":"58","author":"Falcini","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinthera.2011.09.001_bib23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/01.bpo.0000164871.36098.4c","article-title":"Efficacy of oral alendronate in children with osteogenesis imperfecta","volume":"25","author":"Cho","year":"2005","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.clinthera.2011.09.001_bib24","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/lt.20466","article-title":"Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study","volume":"11","author":"Millonig","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.clinthera.2011.09.001_bib25","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","article-title":"Impact of alendronate on quality of life in children with osteogenesis imperfecta","volume":"25","author":"Seikaly","year":"2005","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.clinthera.2011.09.001_bib26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/01.bpo.0000150810.35794.e8","article-title":"Oral bisphosphonates to treat disuse osteopenia in children with disabilities: a case series","volume":"25","author":"Sholas","year":"2005","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.clinthera.2011.09.001_bib27","first-page":"105","article-title":"Alendronate treatment in children with osteogenesis imperfecta","volume":"45","author":"Akcay","year":"2008","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.clinthera.2011.09.001_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/PHM.0b013e3181583ddc","article-title":"Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy","volume":"87","author":"Apkon","year":"2008","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.clinthera.2011.09.001_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.mph.0000210409.48877.c3","article-title":"Osteoporosis in children with severe congenital neutropenia: bone mineral density and treatment with bisphosphonates","volume":"28","author":"Borzutzky","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.clinthera.2011.09.001_bib30","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00467-008-0940-9","article-title":"Bisphosphonates in children with hypercalciuria and reduced bone mineral density","volume":"23","author":"Freundlich","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.clinthera.2011.09.001_bib31","first-page":"894","article-title":"Oral bisphosphonates in polyostotic fibrous dysplasia","volume":"40","author":"Khadilkar","year":"2003","journal-title":"Indian Pediatr"},{"issue":"4 Pt 1","key":"10.1016\/j.clinthera.2011.09.001_bib32","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1542\/peds.102.4.990","article-title":"Bisphosphonates for treatment of childhood hypercalcemia","volume":"102","author":"Lteif","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2011.09.001_bib33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1651-2227.2003.tb00577.x","article-title":"Treatment of children with osteogenesis imperfecta in Estonia","volume":"92","author":"Maasalu","year":"2003","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.clinthera.2011.09.001_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.rhu.0000208490.22492.09","article-title":"Alendronate treatment in osteogenesis imperfecta","volume":"12","author":"Madenci","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2011.09.001_bib35","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1067\/mpd.2001.112473","article-title":"New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment","volume":"138","author":"Mukamel","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinthera.2011.09.001_bib36","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/01.bpo.0000152940.10487.c9","article-title":"Bone healing in children with osteogenesis imperfecta treated with bisphosphonates","volume":"25","author":"Pizones","year":"2005","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.clinthera.2011.09.001_bib37","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jbspin.2004.09.005","article-title":"Effect of alendronate therapy in children with osteogenesis imperfecta","volume":"72","author":"Vyskocil","year":"2005","journal-title":"Joint Bone Spine"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811005534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811005534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T05:06:35Z","timestamp":1712984795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811005534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0149291811005534"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.09.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}